Summarized health data about hip fracture can be accessed by contacting the National Insurance Claims for Epidemiological Research (NICER) Group, School of Public Health, Peking University. Contact email: <0016163159@bjmu.edu.cn>.

Introduction {#sec007}
============

Hip fracture is the most devastating type of osteoporotic fracture because of the associated increased risk of morbidity \[[@pmed.1003180.ref001]\], mortality \[[@pmed.1003180.ref002]--[@pmed.1003180.ref004]\], disability \[[@pmed.1003180.ref005]\] and subsequent hip fracture \[[@pmed.1003180.ref006]\], as well as high societal healthcare costs \[[@pmed.1003180.ref007]\]. Studies have found that the 1-year mortality rate after hip fracture was as high as 22% \[[@pmed.1003180.ref004]\] or even 30% \[[@pmed.1003180.ref002]\]. Among those who survived, 50% lost functional independence, and one-third eventually became fully dependent \[[@pmed.1003180.ref005]\]. With a rapidly aging global population, the hip-fracture-associated burden is expected to become a serious challenge.

It is projected that the number of hip fractures worldwide will increase from 1.26 million in 1990 to 4.5 million by 2050, about half of which are likely to occur in Asia, and particularly in China \[[@pmed.1003180.ref001]\]. However, in the past decade, the incidence of hip fracture in high-income nations has declined or reached a plateau after an initial increase \[[@pmed.1003180.ref008]--[@pmed.1003180.ref013]\]. The vast majority of published studies have been conducted in high-income nations, and the data are scarce in low- or intermediate-income nations \[[@pmed.1003180.ref014]--[@pmed.1003180.ref016]\]. A systematic review conducted in 2014, including 22 studies from high-income nations/regions and 3 from low- or intermediate-income nations, indicated that hip fracture incidence began to decrease after an initial increase in high-income nations/regions, but still increased rapidly in low- or intermediate-income nations \[[@pmed.1003180.ref017]\].

China, the largest low- or intermediate-income nation, has the largest population in the world and has been experiencing unprecedented rapid population aging. In 2018, the proportion of the population aged 65 years and older reached 11.93%, and this percentage is predicted to be 14% in 2025 and about 30% by 2050 \[[@pmed.1003180.ref018]\]. Incidence of hip fracture and associated costs for hospitalization in China may place a significant burden on patients and their families, and are likely to be a challenge to Chinese basic medical insurance, with the increasing reimbursement ratio \[[@pmed.1003180.ref019]\]. However, only a few studies have evaluated trends in hip fracture incidence and costs for hospitalization in China, using relatively small samples (830 \[[@pmed.1003180.ref019]\], 938 \[[@pmed.1003180.ref020]\], and 27,205 \[[@pmed.1003180.ref021]\] patients), often over short time intervals (1 \[[@pmed.1003180.ref020]\], 2 \[[@pmed.1003180.ref021]\], and 3 \[[@pmed.1003180.ref019]\] years) and covering only regional areas \[[@pmed.1003180.ref016],[@pmed.1003180.ref022],[@pmed.1003180.ref023]\].

Accurate information about trends in the incidence of hip fracture and associated costs for hospitalization could ensure appropriate allocation of healthcare resources and effective implementation of policies to alleviate individual and social burdens. This study therefore aimed to evaluate trends in incidence of hip fracture and associated costs for hospitalization in China from 2012 to 2016.

Methods {#sec008}
=======

Data sources {#sec009}
------------

Data on hip fracture were obtained from the Urban Employee Basic Medical Insurance (UEBMI) and Urban Resident Basic Medical Insurance (URBMI) databases \[[@pmed.1003180.ref024]\]. UEBMI covers working and retired employees in cities (i.e., employers and employees from government agencies and institutions, state-owned enterprises, private businesses, social organizations, and other private entities), and URBMI covers citizens without employment in cities (i.e., children, students, elderly people, and unemployed residents). By 2016, UEBMI and URBMI covered over 95% of the whole urban population of China. UEBMI and URBMI are updated on a monthly basis in all cities. Provinces/cities without detailed information on diagnosis were excluded. Data from about 480 million residents in 23 provinces (about 58.5% of the overall urban population in China) were included in this study. The variables included age, sex, International Classification of Diseases (ICD) code and name of primary and secondary diagnosis, and total medical expenses.

Study population {#sec010}
----------------

Data were analyzed from a nationwide population covering approximately 100 million residents aged 55 years and older in 23 provinces over the 5-year period from January 1, 2012, to December 31, 2016. The time period of the study was chosen due to the availability of data. In patients aged 55 years and above, the most common cause of hip fracture is osteoporosis combined with low-energy trauma (generally arising from a fall) \[[@pmed.1003180.ref025]--[@pmed.1003180.ref028]\]. Hip fracture in younger patients is usually caused by high-energy trauma and is not related to osteoporosis \[[@pmed.1003180.ref025]--[@pmed.1003180.ref028]\]. In addition, indicators of osteoporosis such as bone density or imaging information are seldom available in the medical insurance databases. Therefore, consistent with previous publications on hip fracture incidence \[[@pmed.1003180.ref008],[@pmed.1003180.ref009],[@pmed.1003180.ref011],[@pmed.1003180.ref016],[@pmed.1003180.ref029]\], in this study, hip-fracture-related indicators such as the incidence of hip fracture and associated costs in patients aged 55 years and above were used as surrogate indexes for determining the burden of osteoporosis or osteoporotic fractures. The inclusion criteria of the population were individuals who (1) had either UEMBI or URBMI during 2012 to 2016, (2) were enrolled in UEMBI or URBMI in 1 of the 23 provinces included in the study, and (3) were ≥55 years old at the first hip fracture during the study period. Individuals with the following conditions were excluded: (1) without a valid national insurance ID or (2) had conflicting information recorded, i.e., records of medical treatment reimbursement time earlier than the individual's first enrollment time. Insurance data were anonymized for study purposes. The study protocol was approved by the ethical review committee of the Peking University Health Science Center, and the requirement for informed consent was waived (IRB00001052-18012).

Hip fracture identification {#sec011}
---------------------------

We identified hip fracture using ICD-9 code 820 and ICD-10 codes S72.0 and S72.1, following previous studies \[[@pmed.1003180.ref009],[@pmed.1003180.ref015],[@pmed.1003180.ref030],[@pmed.1003180.ref031]\], and medical terms in Chinese including fracture of femoral neck, intertrochanteric fracture, and hip fracture. ICD-10 code S72.2 was excluded because of potential misclassification of femoral shaft fracture. To avoid missing patients when using the medical terms in Chinese, a fuzzy string matching algorithm was constructed to extract potential hip fracture patients from the database. Details of the method used are described in Section I of [S1 Appendix](#pmed.1003180.s001){ref-type="supplementary-material"}. Briefly, the keywords were Chinese diagnostic terms written in different styles, including intracapsular fracture of the femoral neck, basicervical fracture of the femoral neck, subcapital femoral neck fracture, transcervical femoral neck fracture, and reverse obliquity intertrochanteric fracture. Additionally, we included specific symptoms and signs (hip pain, shorting and external rotation of the affected leg), special examination (hip X-ray), and particular treatments (open reduction and internal fixation of femoral neck fracture, open reduction and internal fixation of intertrochanteric fracture).

Exclusion criteria for case identification were the following: (1) pathological fracture, (2) old hip fracture, (3) femoral shaft fracture, (4) distal femoral fracture, (5) subtrochanteric fracture, (6) complications and sequelae of hip fracture (non-union, delayed union, malunion, osteomyelitis, osteoarthritis, and anchylosis), (7) prosthesis complications, (8) osteonecrosis of the femoral head, (9) hip dislocation, and (10) removal of internal fixation devices. In addition, patients with hip fracture have a 2-fold higher risk of second hip fracture than those without prior fracture \[[@pmed.1003180.ref032]\]. Patients were consequently not included as a new case if (1) the fracture occurred within half a year after a previous one (this approach is consistent with previous publications \[[@pmed.1003180.ref008]\]) or (2) the diagnosis text was clearly described as "old hip fracture" by doctors. Diagnostic information in the database of all hip fracture patients was reviewed independently by 2 orthopedic surgeons.

Statistical analysis {#sec012}
--------------------

National incidence for each of the 5 years from 2012 to 2016 was calculated. Incidence was stratified by sex and age (55--64, 65--74, 75--84, and ≥85 years old). Incidence was calculated using a 2-stage approach. Details of the method used to calculate incidence is provided in Section II of [S1 Appendix](#pmed.1003180.s001){ref-type="supplementary-material"}. In brief, we first calculated age- and sex-specific incidence in each province. The denominator used to calculate the annual incidence of hip fracture was the total number of residents in UEBMI and URBMI in each province during the year. The numerator was the number of patients with hip fracture estimated for the denominator population in each province, taking into account missing data. The total enrolled population in each province can be separated into 3 groups: those with no records of a medical claim (*N*~1~), those with complete information on diagnosis in claim records (*N*~2~), and those with claim records missing diagnostic information (*N*~3~). The observed incident patients with hip fracture (*M*~1~) were from *N*~2~, whereas the number of cases (*M*~2~) in *N*~3~ was estimated using a method based on Poisson regression with 10 rounds of multiple imputations. In the second stage, a random-effects meta-analysis was used to pool the province-specific estimates to calculate the national or regional (area) average estimates. We checked that the variance of province-specific estimates was stable using the Freeman--Tukey double arcsine transformation \[[@pmed.1003180.ref033]\]. Incidence was expressed as per 100,000 person-years at risk, and 95% confidence intervals (CIs) were calculated assuming a Poisson distribution. Age-adjusted rates at the national level were calculated using China 2010 census data. Sensitivity analyses were conducted to assess the robustness of the results: (1) including only cases with complete data to assess the lower bounds of the rates and (2) excluding the top 10% of provinces ranked by the missingness of diagnostic information.

We also calculated hip-fracture-associated costs for hospitalization, including total costs and costs per patient. The costs in our study included only costs for inpatient hospitalization, which were categorized as diagnosis-related costs (including imaging investigations such as X-ray, computerized tomography, and magnetic resonance imaging), surgical treatment costs (associated with surgery, anesthesia, and medical materials), and pharmaceutical treatment costs (anti-osteoporosis drugs, etc.). Costs were discounted by the consumer price index (CPI) in each year to 2016 costs and converted into US dollars based on the 2016 RMB to US dollar exchange rate (period average). The CPI and exchange rate were from China Statistical Yearbook 2017.

Student's *t* test for continuous variables and the chi-squared test for categorical variables were used to compare statistics between males and females. The prespecified statistical analysis plan is provided in Section III of [S1 Appendix](#pmed.1003180.s001){ref-type="supplementary-material"}. All statistical analyses used Stata version 15.0, and a 2-sided test with *P* \< 0.05 was considered statistically significant. This study is reported as per the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guideline ([S1 STROBE Checklist](#pmed.1003180.s003){ref-type="supplementary-material"}).

Results {#sec013}
=======

Of all the 480 million residents in 23 provinces in the UEBMI and URBMI databases, a total of 102.56 million participants aged 55 years and older were included in this study ([S1 Table](#pmed.1003180.s004){ref-type="supplementary-material"}), of whom 190,560 were confirmed as having a hip fracture during the study period. The locations of the 23 provinces are shown in [Fig 1](#pmed.1003180.g001){ref-type="fig"}. Most hip fracture patients were Han Chinese (88.85%), 63.99% were female, and 42.88% of fractures occurred in those aged 75--84 years ([Table 1](#pmed.1003180.t001){ref-type="table"}).

![The 23 provinces in China included in the study.\
The geographical base map data were obtained from the Institute of Geographic Sciences and Natural Resources Research, Chinese Academy of Sciences (<http://www.resdc.cn/>). Black dots indicate the included cities in 23 provinces.](pmed.1003180.g001){#pmed.1003180.g001}

10.1371/journal.pmed.1003180.t001

###### Selected characteristics for hip fracture patients grouped by sex.

![](pmed.1003180.t001){#pmed.1003180.t001g}

  Characteristic                                        Subgroup         Total            Male             Female            Sex comparison statistics
  ----------------------------------------------------- ---------------- ---------------- ---------------- ----------------- -----------------------------------------------
  Number                                                                 190,560          68,509           121,933           
  Age, years, mean (SD)                                                  77.05 (8.94)     76.12 (9.08)     77.57 (8.82)      32.855[^a^](#t001fn002){ref-type="table-fn"}
  Age group, *n* (%)                                    55--64           31,600 (16.58)   13,222 (19.30)   18,346 (15.05)    912.884[^b^](#t001fn003){ref-type="table-fn"}
  65--74                                                54,560 (28.63)   20,397 (29.77)   34,127 (27.99)                     
  75--84                                                81,706 (42.88)   27,923 (40.76)   53,749 (44.08)                     
  ≥85                                                   22,681 (11.90)   6,963 (10.16)    15,708 (12.88)                     
  Year, *n* (%)                                         2012             16,587 (8.70)    6,147 (8.97)     10,419 (8.54)     138.404[^b^](#t001fn003){ref-type="table-fn"}
  2013                                                  27,727 (14.55)   9,970 (14.55)    17,742 (14.55)                     
  2014                                                  35,968 (18.87)   13,760 (20.08)   22,204 (18.21)                     
  2015                                                  43,703 (22.93)   15,526 (22.66)   28,164 (23.10)                     
  2016                                                  66,575 (34.94)   23,106 (33.73)   43,404 (35.60)                     
  Ethnicity, *n* (%)                                    Han              169,315(88.85)   61,317 (89.50)   107,898 (88.49)   81.683[^b^](#t001fn003){ref-type="table-fn"}
  Other                                                 17,827 (9.36)    5,882 (8.59)     11,935 (9.79)                      
  Unknown                                               3,418 (1.80)     1,310 (1.91)     2,100 (1.72)                       
  Area[^c^](#t001fn004){ref-type="table-fn"}, *n* (%)   East             76,485 (40.14)   27,022 (39.44)   49,426 (40.54)    223.175[^b^](#t001fn003){ref-type="table-fn"}
  North                                                 4,381 (2.30)     1,875 (2.74)     2,500 (2.05)                       
  North-East                                            29,575 (15.52)   10,321(15.07)    19,253(15.79)                      
  North-West                                            4,284 (2.25)     1,789 (2.61)     2,492 (2.04)                       
  South-Central                                         51,392 (26.97)   18,263 (26.66)   33,110 (27.15)                     
  South-West                                            24,443 (12.83)   9,239 (13.49)    15,152 (12.43)                     

Thirteen patients (0.01%) had missing data for age; 118 patients (0.06%) had missing data for sex; 3,418 patients (1.79%) had missing data for ethnicity.

^a^Student's *t* test.

^b^Chi-squared test.

^c^East area included Jiangsu, Zhejiang, Anhui, Jiangxi, and Shandong provinces; North area included Shanxi and Inner Mongolia provinces; North-East area included Liaoning, Jilin, and Heilongjiang provinces; North-West area included Shaanxi, Gansu, Qinghai, and Xinjiang provinces; South-Central area included Henan, Hubei, Hunan, Guangdong, Guangxi, and Hainan provinces; South-West area included Chongqing, Guizhou, and Yunnan provinces.

SD, standard deviation.

Hip fracture incidence {#sec014}
----------------------

Between 2012 and 2016, the total incidence of hip fracture in those aged 55 years and over was relatively stable, at 148.75 per 100,000 (95% CI 115.32--182.19; *P \<* 0.001) in 2012 and 136.65 per 100,000 (95% CI 109.68--163.62; *P \<* 0.001) in 2016. Similar patterns were also shown for both sexes. For females, the incidence was 180.72 per 100,000 (95% CI 137.16--224.28; *P \<* 0.001) in 2012 and 177.13 per 100,000 (95% CI 139.93--214.33; *P \<* 0.001) in 2016; for males, the incidence was 121.86 per 100,000 (95% CI 97.30--146.42; *P \<* 0.001) in 2012 and 99.15 per 100,000 (95% CI 81.31--116.99; *P \<* 0.001) in 2016 ([Table 2](#pmed.1003180.t002){ref-type="table"}; [Fig 2A](#pmed.1003180.g002){ref-type="fig"}). When considering only cases with complete data, the lower bound of national incidence was 80.47 per 100,000 (95% CI 60.96--99.98; *P \<* 0.001) in 2012 and 96.27 per 100,000 (95% CI 68.92--123.63; *P \<* 0.001) in 2016, with a plateau ([S2 Table](#pmed.1003180.s005){ref-type="supplementary-material"}). The result calculated by excluding the top 10% of provinces in terms of missing diagnostic information was also similar to the pattern reported above ([S2 Table](#pmed.1003180.s005){ref-type="supplementary-material"}). Incidence increased with age, with the highest incidence in patients aged 85 years or older and the lowest incidence in those aged 55--64 years ([Table 2](#pmed.1003180.t002){ref-type="table"}; [Fig 2B](#pmed.1003180.g002){ref-type="fig"}). The decrease was more pronounced for patients aged 65 years or older in both sexes. However, the incidence remained broadly the same in those aged 55--64 years ([Fig 2C and 2D](#pmed.1003180.g002){ref-type="fig"}).

![Crude incidence of hip fracture in the population grouped by sex, age, and sex--age group (per 100,000 person-years).\
(A) Hip fracture incidence by sex and year. (B) Age-specific hip fracture incidence. (C) Age-specific hip fracture incidence for females. (D) Age-specific hip fracture incidence for males.](pmed.1003180.g002){#pmed.1003180.g002}

10.1371/journal.pmed.1003180.t002

###### Crude incidence of hip fracture grouped by sex and age group (per 100,000 person-years).

![](pmed.1003180.t002){#pmed.1003180.t002g}

  Characteristic   Subgroup                  Hip fracture incidence (95% CI) per 100,000 person-years                                                                                 
  ---------------- ------------------------- ---------------------------------------------------------- ------------------------- ------------------------- ------------------------- -------------------------
  Total                                      148.75 (115.32--182.19)                                    164.17 (133.84--194.50)   138.98 (113.16--164.79)   130.11 (105.87--154.34)   136.65 (109.68--163.62)
  Sex              Male                      121.86 (97.30--146.42)                                     105.96 (84.38--127.54)    108.17 (89.05--127.29)    93.80 (76.59--111.00)     99.15 (81.31--116.99)
  Female           180.72 (137.16--224.28)   204.04 (164.86--243.23)                                    165.26 (132.63--197.89)   156.48 (124.78--188.19)   177.13 (139.93--214.33)   
  Age (years)      55--64                    46.30 (34.43--59.93)                                       48.35 (37.80--60.18)      40.32 (31.36--50.42)      36.15 (27.35--46.17)      38.48 (30.64--47.21)
  65--74           131.50 (90.91--179.55)    138.29 (105.14--175.97)                                    113.81 (89.22--141.38)    102.85 (79.93--128.66)    115.16 (91.48--141.57)    
  75--84           342.80 (231.98--475.09)   376.24 (280.45--486.02)                                    319.98 (248.30--400.71)   288.49 (224.37--360.63)   314.99 (248.90--388.82)   
  ≥85              548.87 (363.62--771.87)   633.03 (448.60--848.91)                                    568.47 (415.06--745.79)   529.04 (395.52--681.83)   523.96 (384.99--684.18)   

All rates are significantly larger than 0 with *P* \< 0.001. The linear trend tests overall and for subgroup incidences across the 5 years were not significant (all *P* \> 0.05).

Absolute number of hip fractures {#sec015}
--------------------------------

The overall number of hip fractures was 16,587, 27,727, 35,968, 43,703, and 66,575 for the years 2012, 2013, 2014, 2015, and 2016, respectively ([Table 1](#pmed.1003180.t001){ref-type="table"}; [Fig 3A](#pmed.1003180.g003){ref-type="fig"}). The mean age at the first hip fracture rose from 76.07 (SD 9.43) to 77.77 (SD 8.66) years over the 5-year period (*P* \< 0.001; [S1 Fig](#pmed.1003180.s002){ref-type="supplementary-material"}); the proportion of females was 62.89% in 2012, and increased to 65.26% in 2016 (*P* \< 0.001).

![Annual number of hip fracture patients and associated costs for hospitalization (in US dollars).\
(A) Annual number of hip fractures. (B) Total costs for hospitalization. (C) Costs for hospitalization per patient. Costs were discounted by the consumer price index (CPI) in each year to 2016 costs and converted into US dollars based on the 2016 RMB to US dollar exchange rate (period average). The CPI and exchange rate were from China Statistical Yearbook 2017.](pmed.1003180.g003){#pmed.1003180.g003}

Standardization {#sec016}
---------------

When the incidence was standardized to the China 2010 census population, the total adjusted incidence of hip fracture was 128.10 (95% CI 88.68--174.79; *P \<* 0.001) per 100,000 in 2012 and 114.46 (95% CI 89.85--142.06; *P \<* 0.001) per 100,000 in 2016 ([S3 Table](#pmed.1003180.s006){ref-type="supplementary-material"}).

Costs for hospitalization for hip fractures {#sec017}
-------------------------------------------

The total costs for hospitalization for hip fracture patients over the study period were US\$1.049 billion, with an average of US\$6,690 per patient. Total costs for hospitalization increased about 6-fold, from US\$60 million in 2012 to US\$380 million in 2016, while the costs per patient increased only 1.59-fold, from US\$4,300 in 2012 to US\$6,840 in 2016 ([Fig 3B and 3C](#pmed.1003180.g003){ref-type="fig"}).

Discussion {#sec018}
==========

Using a nationally representative database covering approximately 480 million residents in 2012--2016, this study found that hip fracture incidence in China reached a plateau. In both females and males, there was a decline in incidence in patients aged over 65 years, and incidence remained stable for those aged 55 to 64 years. However, the absolute number of hip fractures and associated costs for hospitalization increased rapidly.

The incidence of hip fracture has been shown to increase exponentially with advancing age \[[@pmed.1003180.ref034]\], so it seemed likely that crude incidence would increase rapidly in China alongside the aging population. In our study, this plateauing incidence was very different from the previous rapid increase reported by Xia et al. in Beijing, China \[[@pmed.1003180.ref016]\], or the pattern found in other low- or intermediate-income nations such as South Africa \[[@pmed.1003180.ref014]\] and Kuwait \[[@pmed.1003180.ref015]\]. However, most high-income nations, such as the US \[[@pmed.1003180.ref008]\], Canada \[[@pmed.1003180.ref009]\], Finland \[[@pmed.1003180.ref010]\], France \[[@pmed.1003180.ref011]\], Australia \[[@pmed.1003180.ref012]\], and Sweden \[[@pmed.1003180.ref013]\], have reported a plateau or continuing decline after an initial increase. A similar pattern of age-adjusted incidence lagging about 1 decade behind that of high-income countries was also found in Taiwan \[[@pmed.1003180.ref035]\] and Hong Kong \[[@pmed.1003180.ref036]\], 2 other economically advanced regions in China. The Hong Kong study additionally suggested that the decline may continue to occur a few years later in other Asian countries \[[@pmed.1003180.ref036]\], and the speculation was recently confirmed in Singapore using national medical insurance claims data covering up to 5.6 million population \[[@pmed.1003180.ref037]\]. In fact, Singapore and China were predicted to have a rapid rise in hip fracture incidence in the studies by Xia et al. and Koh et al. \[[@pmed.1003180.ref016],[@pmed.1003180.ref038]\], but the latest data from both countries (Yong et al.'s study for Singapore \[[@pmed.1003180.ref037]\] and our study for China) do not present that anticipated rising tendency. Additionally, a recent study reported that the hip fracture incidence decreased slightly in males and slowly increased in females in Tangshan city in China \[[@pmed.1003180.ref022]\]. Hip fracture incidence in China between 2012 and 2016 may follow the same pattern as previously reported for most high-income nations.

However, the exact reasons for the plateau of hip fracture incidence in China have not been clearly explained. The rate of hip fracture among patients aged 55 years and above has been considered as the best estimate of osteoporosis or osteoporotic fractures \[[@pmed.1003180.ref025],[@pmed.1003180.ref039]\]. Public health efforts regarding osteoporosis prevention and therapy in China might play an important role in this plateau of hip fracture incidence. First, 2 critical documents concerning prevention and treatment of osteoporosis, "Key Points on the Prevention and Treatment of Osteoporosis" \[[@pmed.1003180.ref040]\] and "Guidelines for the Diagnosis and Treatment of Primary Osteoporosis" \[[@pmed.1003180.ref041]\], were both issued in 2011 in China. Since then, osteoporosis has been listed as one of the National Health Priorities. The diagnosis rate of hip fracture and relevant preventive strategies were also subsequently improved after the release of the Chinese guidelines \[[@pmed.1003180.ref042],[@pmed.1003180.ref043]\]. Similar policies and a decline of hip fracture incidence have also been seen in Taiwan of China since 2004 \[[@pmed.1003180.ref044]\]. Second, zoledronic acid, available by prescription to postmenopausal women as the first-line treatment to prevent osteoporosis and reduce the risk of hip, vertebral, and other fractures \[[@pmed.1003180.ref045]\], entered the Chinese market in 2009. Teriparatide, a novel bone anabolic agent, entered in 2011. Research showed that use of anti-osteoporotic drugs combined with calcium/vitamin D can reduce risk of re-fracture and mortality by 72.2% and 64%, respectively, compared with no treatment \[[@pmed.1003180.ref046]\]. Studies in the US \[[@pmed.1003180.ref008]\] and Hong Kong \[[@pmed.1003180.ref036]\] suggested that the number of anti-osteoporosis treatments may be associated with the decline in hip fracture incidence, whereas a few other studies doubted this, as the decline appeared before the availability of bisphosphonate \[[@pmed.1003180.ref009],[@pmed.1003180.ref047]\]. It is not clear and hard to determine how much the use of anti-osteoporotic medication accounts for the reduction of hip fracture incidence. However, the plateau occurred in China after 2012, which was close to the market release of zoledronic acid (2009) and teriparatide (2012). In addition, the rapid increase in use of anti-osteoporosis drugs was reported in different regions between 2008 and 2012 in China \[[@pmed.1003180.ref048],[@pmed.1003180.ref049]\]. Compared with the hip fracture incidence during 2002--2006 in Beijing, China (229 per 100,000 person-years in females and 129 per 100,000 person-years in males) \[[@pmed.1003180.ref016]\], the hip fracture incidence in our study was lower in both females and males, especially in 2016. Therefore, we speculate that the widespread prescription of anti-osteoporotic drugs might have had an important impact on osteoporosis, and resulted in this plateau of hip fracture incidence. However, we acknowledge that, due to missing information on use of individual osteoporotic drugs, we cannot draw a direct causal relationship, and therefore further studies are still needed. Third, over 90% of hip fractures are attributed to a simple fall \[[@pmed.1003180.ref050]\]. "Guidelines on Technical Interventions for Fall Prevention in Older People" was released by the Ministry of Health in China in 2011 \[[@pmed.1003180.ref051]\]. Fall prevention strategies for secondary prevention of hip fracture have been identified as effective and have increased significantly in China, which may also have partly contributed to this plateau of hip fracture incidence \[[@pmed.1003180.ref052],[@pmed.1003180.ref053]\].

In this study, the largest percentage decline in hip fracture incidence was in individuals aged 65 years and older in both males and females. In contrast, hip fracture incidence in those aged 55--64 years remained broadly constant from 2012 to 2016. These findings are consistent with findings in the US \[[@pmed.1003180.ref008]\], France \[[@pmed.1003180.ref011]\], and Taiwan of China \[[@pmed.1003180.ref044]\], where older people showed a more pronounced decline. The underlying mechanism may be that older people benefit more from the prevention and treatment of osteoporosis because most hip fractures in this group are osteoporotic fractures caused by low-energy trauma \[[@pmed.1003180.ref025]\].

Hip fracture incidence seemed to be stabilizing in China, but the number of hip fractures increased in all age groups in both males and females over the 5-year period. Our study found that the absolute number of hip fractures increased 4-fold. This was consistent with previous reports in Finland \[[@pmed.1003180.ref054]\] and the US \[[@pmed.1003180.ref055]\], where the number of hip fractures was also predicted to increase despite a decline in incidence. This apparent contradiction might reflect the serious aging problem in China. The mean age at first hip fracture increased in this study, which may also suggest the influence of an aging society.

The rapid increase of the absolute number of hip fractures meant that there was an approximate 6-fold increase in total annual costs for hospitalization for hip fracture from 2012 to 2016. Costs per patient also increased 1.59-fold. As mentioned above, Chinese guidelines and policies about osteoporosis prevention and therapy were issued in 2011, which encouraged doctors to prescribe medical treatments to these patients. In addition, costs of inpatient drugs containing anti-osteoporosis medication were reported to account for 25.2% of the total direct costs for osteoporotic fractures \[[@pmed.1003180.ref020]\]. With the market release of zoledronic acid (2009) and teriparatide (2012), anti-osteoporosis drugs became more accessible. A rapid increase in the use of these drugs was also reported \[[@pmed.1003180.ref048],[@pmed.1003180.ref049]\]. In addition, the increases in costs of surgery and associated medical materials might also contribute to the increase of the costs per patient. With a rapidly aging population, it is predicted that the percentage of the population aged 65 years and over will increase dramatically from about 11.93% in 2018 to 14% in 2025 and 30% by 2050 \[[@pmed.1003180.ref018]\]. China is facing rapid population aging at a relatively early stage in its economic development. In addition, according to 2010 statistical data, there were only about 50,000 Chinese orthopedic surgeons, serving about 1.34 billion people \[[@pmed.1003180.ref056]\]. Population aging and the increase in hip-fracture-associated costs for hospitalization are likely to become substantial challenges for clinicians and health policy-makers over the next generation, as they struggle to provide high-quality, cost-effective care to patients.

Strengths and limitations {#sec019}
-------------------------

This study used a large, nationally representative sample of the Chinese mainland population, giving good estimates of the incidence and costs for hospitalization of hip fracture. It allowed us not only to provide an overall estimation of incidence rates but also to explore age and sex patterns in the rates across the country. This study also has several limitations. First, the database did not cover rural areas, which have a different insurance system. However, the combined basic population structure was close to the distribution in the China 2010 population census data. Second, missing diagnostic variables could have affected the estimates. However, sensitivity analyses were used to explore the potential influence of these on the estimations. These included presenting the lower bound of the rates using only cases with complete data, to facilitate the interpretation of the findings. Finally, case ascertainment was limited, because the basic medical insurance databases did not provide information about laboratory data, imaging information, detailed surgical procedures, and cause of death. We were also unable to contact patients directly to obtain additional information because of the anonymity requirement.

Conclusion {#sec020}
----------

The incidence of hip fracture among patients aged 55 years and over in China reached a plateau between 2012 and 2016. However, the absolute number of hip fractures and associated medical costs for hospitalization increased rapidly because of population aging. Further decline in hip fracture incidence is needed to reduce the absolute number of fractures and the socioeconomic burden.
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Dear Dr. Zhan,

Thank you very much for submitting your manuscript \"Trends in Hip Fracture Incidence and Costs in China: A National Population Based Study, 2012-2016\" (PMEDICINE-D-20-00290R1) for consideration at PLOS Medicine.

Your paper was evaluated by a senior editor and discussed among all the editors here. It was also discussed with an academic editor with relevant expertise, and sent to independent reviewers, including a statistical reviewer. The reviews are appended at the bottom of this email and any accompanying reviewer attachments can be seen via the link below:
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In light of these reviews, I am afraid that we will not be able to accept the manuscript for publication in the journal in its current form, but we would like to consider a revised version that addresses the reviewers\' and editors\' comments. Obviously we cannot make any decision about publication until we have seen the revised manuscript and your response, and we plan to seek re-review by one or more of the reviewers.
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\*\*\*Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.\*\*\*

We ask every co-author listed on the manuscript to fill in a contributing author statement, making sure to declare all competing interests. If any of the co-authors have not filled in the statement, we will remind them to do so when the paper is revised. If all statements are not completed in a timely fashion this could hold up the re-review process. If new competing interests are declared later in the revision process, this may also hold up the submission. Should there be a problem getting one of your co-authors to fill in a statement we will be in contact. YOU MUST NOT ADD OR REMOVE AUTHORS UNLESS YOU HAVE ALERTED THE EDITOR HANDLING THE MANUSCRIPT TO THE CHANGE AND THEY SPECIFICALLY HAVE AGREED TO IT. You can see our competing interests policy here: <http://journals.plos.org/plosmedicine/s/competing-interests>.

Please use the following link to submit the revised manuscript:

<https://www.editorialmanager.com/pmedicine/>

Your article can be found in the \"Submissions Needing Revision\" folder.

To enhance the reproducibility of your results, we recommend that you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see <http://journals.plos.org/plosmedicine/s/submission-guidelines#loc-methods>.

Please ensure that the paper adheres to the PLOS Data Availability Policy (see <http://journals.plos.org/plosmedicine/s/data-availability>), which requires that all data underlying the study\'s findings be provided in a repository or as Supporting Information. For data residing with a third party, authors are required to provide instructions with contact information for obtaining the data. PLOS journals do not allow statements supported by \"data not shown\" or \"unpublished results.\" For such statements, authors must provide supporting data or cite public sources that include it.
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a\) If the data are freely or publicly available, note this and state the location of the data: within the paper, in Supporting Information files, or in a public repository (include the DOI or accession number).
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Last sentence of methods and findings should highlight a limitation of the study methodology/study design

Please provide brief demographics of the cohort

Conclusions- unclear how hip fractures over 55 are a surrogate for osteoporotic fractures. Please clarify and revise as needed

\* Please address the study implications without overreaching what can be concluded from the data; the phrase \"In this study, we observed \...\" may be useful.

\* Please interpret the study based on the results presented in the abstract, emphasizing what is new without overstating your conclusions.

\* Please avoid vague statements such as \"these results have major implications for policy/clinical care\". Mention only specific implications substantiated by the results.

\* Please avoid assertions of primacy (\"We report for the first time\....\")

Author summary

Please use an alternative for "most developed countries". Do you mean specific countries or high-income nations?

I'm not sure this can be directly inferred from your data so please revise "Our findings indicated that strategies for osteoporosis prevention and therapy may have been effective in China over the past few years"

Please rephrase "unparallel trends" to simpler and more accessible language

Introduction

Since you cite previous studies on a similar topic, and note that they evaluated costs over a short time interval, please comment on why 3 years is considered a short time period but 4 (as in this case) isn't?

Please address past research and explain the need for and potential importance of your study. Indicate whether your study is novel and how you determined that. If there has been a systematic review of the evidence related to your study (or you have conducted one), please refer to and reference that review and indicate whether it supports the need for your study.

Methods

Please ensure that the study is reported according to the STROBE guideline. Please add the following statement, or similar, to the Methods: \"This study is reported as per the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guideline (SI file xxx).\"

Did your study have a prospective protocol or analysis plan? Please state this (either way) early in the Methods section.

a\) If a prospective analysis plan (from your funding proposal, IRB or other ethics committee submission, study protocol, or other planning document written before analyzing the data) was used in designing the study, please include the relevant prospectively written document with your revised manuscript as a Supporting Information file to be published alongside your study, and cite it in the Methods section. A legend for this file should be included at the end of your manuscript.

b\) If no such document exists, please make sure that the Methods section transparently describes when analyses were planned, and when/why any data-driven changes to analyses took place.

c\) In either case, changes in the analysis\-- including those made in response to peer review comments\-- should be identified as such in the Methods section of the paper, with rationale.

Please clarify why the time period 2012-2016 was chosen?

Please describe the inclusion and exclusion criteria in full- including age/co-morbidities etc

Please consider adding a map of the cities covered in this database? This might help with visibility and to demonstrate nationwide relevance of these data

Please clarify how you determined the age cut off of 55 years?

Please describe the adjustments with China 2010 census data in the methods as noted in Fig 1. Same goes for the cost discounted using CPI, exchange rate etc in Fig 3

Please provide details of algorithm used and revise the term "relatively loose" to use more appropriate scientific language

Please provide the keywords used (original language and English translation) as supplementary information such that the search may be replicated.

STROBE checklist- please remove page numbers as these are likely to change. Instead you may use paragraphs and sections

Please revise "nearly decreasing trend" and use specific language instead

Please provide p values along with 95% confidence intervals. Please note exact p values should be provided if p\>0.05 or p\<0.05, p\<0.001 is permitted.

Discussion

Please present and organize the Discussion as follows: a short, clear summary of the article\'s findings; what the study adds to existing research and where and why the results may differ from previous research; strengths and limitations of the study; implications and next steps for research, clinical practice, and/or public policy; one-paragraph conclusion.

Please clarify if zoledronic acid is provided to those at risk of osteoporosis or is available over the counter etc

Comments from the reviewers:

Reviewer \#1: Comments to Authors

Overall, this is a well-written and interesting manuscript describing the incidence and costs of hip fractures in China.

There are only a few minor points that could be clarified prior to publication:

1\. The English language is very good, there are just a few minor grammatical issues which can be edited during the production process.

2\. The sentence \"Further decline is needed to reduce the absolute number of fractures and socioeconomic burden resulting from population aging\" is a clear conclusion. It would be better if the similar sentences in the Abstract and Conclusion could be replaced by this sentence instead. i.e. use this sentence instead of \"Further decline is needed to reduce the heavy burden imposed by hip fracture\".

3\. In the Introduction section, it would be useful to provide a reference for the sentence \"It is projected that the number of hip fractures worldwide...\"

4\. It would be useful to move the sentence \"To reduce double-counting, subsequent fractures were considered...\" to the section titled \"Hip Fracture Identification.\"

5\. In the Results section, it could be useful to include a paragraph describing the absolute number of fractures.

6\. In the Discussion section, could the authors discuss the reasons that the costs per patient for hip fracture have increased? The authors have provided an excellent discussion regarding the number and rates of hip fractures, if they could also discuss costs per patient, that would strengthen the Discussion further.

7\. References 15 and 16 do not seem to be appropriate. It seems that these references were used because the authors used similar methods. It would be useful if the authors could find the original reference for that method. Otherwise, they should specify in the text that they completed their analyses using methods similar to these other studies.

8\. Reference 29 does not seem to be properly listed. Could the authors please check this?

9\. In Table 1 and Figure S1, the authors report both median and mean ages. If the data is normally distributed, the authors should report age as mean±SD. If not, then median(IQR). Could the authors please check their data and use either mean or median, but not both?

10\. A map of the region would be useful, instead of a list of provinces (Table S1). Could the authors please provide a map, which will help international readers understand the region better?

11\. Could the authors please provide a more descriptive caption for Table S3?

Reviewer \#2: I confine my remarks to statistical aspects of this paper. These were very well done, but I have a couple of minor points to address before I can recommend publication.

Overall, I would de-emphasize discussion of trends. The data in the table and figures don\'t show a linear trend and it\'s hard to see what trend they might show. It looks like noise.

In Table 1, I would delete the p values - with N this large, everything is significant. And please list what staistic (t, chi square or whatever) is in the \"Statistics\" column

Figures 1 and 3 - I don\'t really like graphs with two axes - changing the limits of either axis changes the appearance a lot. Decide on what you want to show. If it\'s the relation between total cases and incidence/cost then a ratio could be plotted, or you can make a scatter plot of the two, with directed arrows showing trend over time. If that is not what you want to show, then either show only one set of data or adapt something to sut what you want to show.

Peter Flom

Reviewer \#3: The methods are too brief to allow the reader to understand the results and require more detail.

1\. Case ascertainment is very important. More information is needed for the natural language processing in terms of training and test, internal / external validation. Were there changes in the quality of the text records over time.

2\. What proportion of patients had surgery, did this change over time. Usually validation of cases requires surgical / procedure codes. Were the types of patients identified by procedure codes different to those without.

3\. What is the definition of old hip fracture.

4\. How were cases really validated. It seems unfeasible for two surgeons to validate 190,560 cases.

5\. The numerator is described as taking into account missing data. What does this mean? Imputation?

6\. The incidence seems to be per province population. I assume there was standardisation for both age and sex.

7\. Is the reason for the decrease in incidence per population due to differences in age demographic over time.

8\. It is not clear how costs were calculated and over what time period. This needs to be added to the methods

9\. What was the one year mortality, did it vary over time, sex and age group.

10\. Reductions in age specific hip fracture rates have been seen in other populations, often preceding DXA and pharmacological uptake in the community. Please comment

Any attachments provided with reviews can be seen via the following link:

\[LINK\]
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Dear Dr. Zhan,

Thank you very much for re-submitting your manuscript \"Incidence of and trends in hip fracture among adults in urban China: a nationwide retrospective cohort study\" (PMEDICINE-D-20-00290R2) for review by PLOS Medicine.

I have discussed the paper with my colleagues and the academic editor and it was also seen again by xxx reviewers. I am pleased to say that provided the remaining editorial and production issues are dealt with we are planning to accept the paper for publication in the journal.

The remaining issues that need to be addressed are listed at the end of this email. Any accompanying reviewer attachments can be seen via the link below. Please take these into account before resubmitting your manuscript:

\[LINK\]

Our publications team (<plosmedicine@plos.org>) will be in touch shortly about the production requirements for your paper, and the link and deadline for resubmission. DO NOT RESUBMIT BEFORE YOU\'VE RECEIVED THE PRODUCTION REQUIREMENTS.

\*\*\*Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.\*\*\*

In revising the manuscript for further consideration here, please ensure you address the specific points made by each reviewer and the editors. In your rebuttal letter you should indicate your response to the reviewers\' and editors\' comments and the changes you have made in the manuscript. Please submit a clean version of the paper as the main article file. A version with changes marked must also be uploaded as a marked up manuscript file.

Please also check the guidelines for revised papers at <http://journals.plos.org/plosmedicine/s/revising-your-manuscript> for any that apply to your paper. If you haven\'t already, we ask that you provide a short, non-technical Author Summary of your research to make findings accessible to a wide audience that includes both scientists and non-scientists. The Author Summary should immediately follow the Abstract in your revised manuscript. This text is subject to editorial change and should be distinct from the scientific abstract.

We expect to receive your revised manuscript within 1 week. Please email us (<plosmedicine@plos.org>) if you have any questions or concerns.

We ask every co-author listed on the manuscript to fill in a contributing author statement. If any of the co-authors have not filled in the statement, we will remind them to do so when the paper is revised. If all statements are not completed in a timely fashion this could hold up the re-review process. Should there be a problem getting one of your co-authors to fill in a statement we will be in contact. YOU MUST NOT ADD OR REMOVE AUTHORS UNLESS YOU HAVE ALERTED THE EDITOR HANDLING THE MANUSCRIPT TO THE CHANGE AND THEY SPECIFICALLY HAVE AGREED TO IT.

Please ensure that the paper adheres to the PLOS Data Availability Policy (see <http://journals.plos.org/plosmedicine/s/data-availability>), which requires that all data underlying the study\'s findings be provided in a repository or as Supporting Information. For data residing with a third party, authors are required to provide instructions with contact information for obtaining the data. PLOS journals do not allow statements supported by \"data not shown\" or \"unpublished results.\" For such statements, authors must provide supporting data or cite public sources that include it.

If you have any questions in the meantime, please contact me or the journal staff on <plosmedicine@plos.org>.

We look forward to receiving the revised manuscript by May 27 2020 11:59PM.

Sincerely,

Adya Misra, PhD

Senior Editor

PLOS Medicine
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Abstract conclusions

Please start this section with " our results show.." or similar

In the abstract, please clarify if the numbers in brackets represent ranges or 95% confidence intervals? It would be god to clarify this within the entire text as well, where you may have provided one or the other. Please also provide p values, where you provide 95% Confidence intervals

Please use the \"Vancouver\" style for reference formatting, and see our website for other reference guidelines <https://journals.plos.org/plosmedicine/s/submission-guidelines#loc-references>

Please add a single sentence referring to Figure 1 within the main text. Could you confirm that this is an original image and there are no copyright restrictions on sharing this map?

Please state whether any changes were made to the prespecified analyses, within the methods section

Please ensure the reference brackets are placed after a space in text and then followed by full stop or comma as needed. For example xxx \[1,2\].

Comments from Reviewers:

Reviewer \#1: The authors have done an excellent job of responding to all the reviewer and editor comments. I believe that this manuscript is now acceptable for publication.

Reviewer \#2: The authors have addressed my concerns and I now recoomend publication.

Peter Flom

Any attachments provided with reviews can be seen via the following link:
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10.1371/journal.pmed.1003180.r005
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Dear Prof. Zhan,

On behalf of my colleagues and the academic editor, Dr. Kassim Javaid, I am delighted to inform you that your manuscript entitled \"Incidence of and trends in hip fracture among adults in urban China: a nationwide retrospective cohort study\" (PMEDICINE-D-20-00290R3) has been accepted for publication in PLOS Medicine.

PRODUCTION PROCESS

Before publication you will see the copyedited word document (in around 1-2 weeks from now) and a PDF galley proof shortly after that. The copyeditor will be in touch shortly before sending you the copyedited Word document. We will make some revisions at the copyediting stage to conform to our general style, and for clarification. When you receive this version you should check and revise it very carefully, including figures, tables, references, and supporting information, because corrections at the next stage (proofs) will be strictly limited to (1) errors in author names or affiliations, (2) errors of scientific fact that would cause misunderstandings to readers, and (3) printer\'s (introduced) errors.

If you are likely to be away when either this document or the proof is sent, please ensure we have contact information of a second person, as we will need you to respond quickly at each point.

PRESS

A selection of our articles each week are press released by the journal. You will be contacted nearer the time if we are press releasing your article in order to approve the content and check the contact information for journalists is correct. If your institution or institutions have a press office, please notify them about your upcoming paper at this point, to enable them to help maximize its impact.

PROFILE INFORMATION

Now that your manuscript has been accepted, please log into EM and update your profile. Go to <https://www.editorialmanager.com/pmedicine>, log in, and click on the \"Update My Information\" link at the top of the page. Please update your user information to ensure an efficient production and billing process.

Thank you again for submitting the manuscript to PLOS Medicine. We look forward to publishing it.

Best wishes,

Adya Misra, PhD

Senior Editor

PLOS Medicine

[plosmedicine.org](http://plosmedicine.org)
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